OBIO
Orchestra BioMed Holdings, Inc. NASDAQ$4.02
Mkt Cap $235.3M
52w Low $2.20
56.5% of range
52w High $5.42
50d MA $4.34
200d MA $3.78
P/E (TTM)
-3.6x
EV/EBITDA
-3094.3x
P/B
2335.3x
Debt/Equity
0.0x
ROE
-52.8%
P/FCF
-3221.9x
RSI (14)
—
ATR (14)
—
Beta
0.60
50d MA
$4.34
200d MA
$3.78
Avg Volume
204.0K
About
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical devic…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.38 | 0.26 | +168.4% | 4.38 | +0.0% | -4.1% | +3.9% | +5.3% | +3.0% | +5.9% | — |
| Nov 10, 2025 | AMC | -0.38 | -0.40 | -5.3% | 3.78 | -0.8% | +8.5% | +16.9% | +10.6% | +4.2% | +9.3% | — |
| Aug 12, 2025 | AMC | -0.51 | -0.50 | +2.0% | 2.72 | -0.7% | -2.2% | -2.2% | -5.5% | -3.3% | -6.2% | — |
| Apr 2, 2025 | AMC | -0.43 | -0.43 | +0.0% | 3.52 | -8.8% | -11.6% | -21.6% | -19.6% | -20.7% | -16.8% | — |
| Mar 26, 2025 | AMC | -0.43 | -0.37 | +14.0% | 4.38 | +4.1% | +5.0% | +0.5% | -2.3% | -26.0% | -19.6% | — |
| Nov 12, 2024 | AMC | -0.44 | -0.41 | +6.8% | 5.66 | +5.8% | +7.2% | +9.7% | +3.2% | +3.0% | -8.7% | — |
| Aug 12, 2024 | AMC | -0.41 | -0.45 | -9.8% | 6.11 | +2.3% | -2.5% | -9.3% | -0.8% | +5.1% | +4.6% | — |
| May 13, 2024 | AMC | -0.40 | -0.38 | +5.0% | 4.60 | +0.0% | +13.0% | +4.6% | +0.4% | +13.3% | +13.7% | — |
| Mar 27, 2024 | AMC | -0.38 | -0.37 | +2.6% | 5.31 | -1.3% | -0.8% | -6.8% | -5.1% | -7.7% | -6.4% | — |
| Nov 13, 2023 | AMC | -0.39 | -0.38 | +2.6% | 6.04 | -4.0% | +13.1% | +17.9% | +15.6% | +12.4% | +11.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $4.60 | $4.61 | +0.2% | -4.8% | -8.7% | -1.1% | +0.2% | -2.0% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $4.84 | $4.96 | +2.5% | -0.8% | -3.7% | -11.6% | -7.9% | -13.8% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $4.42 | $4.38 | -0.9% | -5.4% | -10.9% | -6.6% | -4.3% | +5.4% |
| Nov 12 | Barclays | Maintains | Overweight → Overweight | — | $4.10 | $4.17 | +1.7% | +7.8% | +2.0% | -3.9% | +0.7% | +3.2% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.73 | +0.4% | +0.7% | +1.1% | +0.4% | -0.4% | -4.0% |
| Aug 20 | BTIG | Downgrade | Buy → Neutral | — | $2.55 | $2.56 | +0.4% | -4.7% | -2.4% | +0.0% | +2.0% | +17.6% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.72 | $2.70 | -0.7% | -2.2% | -2.2% | -5.5% | -3.3% | -6.2% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.64 | $2.68 | +1.5% | -1.5% | +2.7% | -4.5% | +3.0% | +0.8% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.65 | $2.72 | +2.6% | +10.9% | +6.4% | +9.1% | +9.4% | +10.2% |
| May 5 | Barclays | Maintains | Overweight → Overweight | — | $2.74 | $2.66 | -2.9% | -6.6% | -11.7% | -10.2% | +4.7% | -3.3% |
Recent Filings
Data updated apr 26, 2026 4:46pm
· Source: massive.com